EGFR and non-small cell lung carcinoma: Moreover, a phase II study suggested that toripalimab plus chemotherapy was effective in NSCLC patients with EGFR mutation who did not acquire T790M mutation after EGFR-TKI failure (median PFS: 7.0 months, ORR:50%) [13].